We’ve rebranded some of our products, learn more ›
PhenoCycler™ (formerly CODEX®)
PhenoImager HT (formerly Vectra® Polaris™)
Image shows immune cell activity in psoriasis rash. Human fresh frozen tissue was stained with a 23-plex mixed epithelial and immune cell antibody panel to visualize epithelial and vascular markers and survey the immune landscape of skin inflammation in psoriasis. (PanCK – white, CD49f – green, CD138 – red, Podoplanin – blue, CD45 – yellow, CD34 – cyan, CD31– magenta). Credit: Akoya Biosciences
Standard Akoya Biosciences Logo
Black Akoya Biosciences Logo
White Akoya Biosciences Logo
Stacked Akoya Biosciences Logo
Black, Stacked Akoya Biosciences Logo
White, Stacked Akoya Biosciences Logo
See our news releases page for a complete list of press releases.
See our blog page for a complete list of posts.
Central nervous system tissue which typically has high autofluorescence can be routinely studied using the PhenoImager HT (formerly Vectra® Polaris™).
Highly multiplexed single-cell spatial analysis of tissue specimens using PhenoCycler (formerly CODEX).
Introduction to Spatial Phenotyping for Discovery Biology
Introduction to Spatial Phenotypic Signatures for Clinical Research
Synopsis: In a seminal multi-institutional study, published in JAMA Oncology in 2019 , a group of leading immuno-oncology experts determined that spatial phenotypic signatures, measured by multiplex immunofluorescence (mIF), outperformed other biomarker testing approaches in predicting response to anti-PD-1/PD-L1 treatments. The study was conducted by scientists at Johns Hopkins University, Yale University, Vanderbilt University, and Northwestern University.
The authors reviewed published data from more than 50 studies covering more than 10 types of cancer and over 8,000 patients. The mIF studies featured in this paper cite the use of Akoya’s Phenoptics™ platform.
Synopsis: In a truly unique approach taken by scientists at Johns Hopkins University (JHU), Dr. Janis Taube, a leading pathology expert and Dr. Alex Szalay, a world-renowned astrophysicist, joined forces to solve the big data challenge in cancer biomarker discovery. They built a platform titled, AstroPath™ and applied celestial object mapping algorithms to the study of the tumor microenvironment, enabling rapid probabilistic studies of how tumor and immune cells organize and interact to influence treatment response.
The underlying image-capture technology for AstroPath is the PhenoImager HT (formerly Vectra® Polaris™), as part of an ongoing collaboration between Akoya and JHU. The result was the groundbreaking discovery of a spatial biomarker signature which is highly predictive of immunotherapy response in melanoma cases. The study was published in Science in 2021.
Interviewee: JC Villasboas, MD, Mayo Clinic
Synopsis: Dr. JC Villasboas, a physician-scientist and Director of the Immune Monitoring Core Facility at the Mayo Clinic, and his team of collaborators are developing what they call The Cancer Immunome Project. This is a comprehensive effort to fully characterize the immune system and how it interacts with and fights off cancer.
In the interview, Dr. Villasboas says the immune system is of such complexity that it took the addition of new spatial biology tools, namely Akoya’s PhenoCycler system—to be able to comprehensively tackle such a project.
Speaker: Jérôme Galon, PhD, INSERM, Paris
Synopsis: ImmunoScore is one of the first spatial biomarker signatures listed in the WHO and ESMO guidelines and is used to refine the prognosis of patients with localized colon cancer (Stage II and III cases). Dr. Galon, Director of the Laboratory of Integrative Cancer Immunology at INSERM, Paris, pioneered the development of the ImmunoScore test.
In this Science webcast, Dr. Galon gives an educational overview of the immune landscape of cancer and provides a summary of latest studies to profile ImmunoScore and other immune signatures in metastatic colorectal cancer (Stage IV cases). Leveraging a suite of multi-omics tools, Dr. Galon cites the use of Akoya’s multispectral imaging technology, Phenoptics, to quantify the spatial relationships of diverse cell phenotypes in the tumor microenvironment.
Speaker: Alexander Borowsky, MD, UC Davis
Synopsis: Akoya, UCSF and the I-SPY trial consortium have an ongoing collaboration to leverage the Phenoptics™ platform for developing predictive and prognostic biomarkers, particularly for use in selecting the most effective neoadjuvant and adjuvant immunotherapies for patients with early breast cancer. At the Society for Immunotherapy of Cancer 2020 Annual Meeting, Dr. Borowsky presented preliminary results from the I-SPY2 trial where he showed how spatial proximity scores between tumor and immune cells are correlated to treatment response.
Speaker: Kai Kessenbrock, PhD, UC Irvine
Synopsis: The mission of the Human Cell Atlas is to create comprehensive reference maps of all human cells to describe and define the cellular basis of health and disease. Using the Human Breast Cell Atlas project as an example, Dr. Kessenbrock explains how his team discovered unique cellular niches within the breast tissue microenvironment and how their spatial proximity gives us a more comprehensive view of the biology underlying each sample.
Dr. Kessenbrock’s lab complements single-cell RNA sequencing data with single-cell spatial mapping data from the CODEX® platform to generate an atlas of human breast tissue.
Synopsis: In this multi-part webinar series, the speakers review analytical frameworks and algorithms to integrate imaging-based single-cell data with complementary transcriptomic and genomic datasets.
The experts combined CODEX® with single-cell sequencing data to generate multi-omic spatial maps of tissue samples. The speakers cite the ability of the CODEX platform to generate high resolution maps of millions of cells across whole tissue samples as one of the key reasons for integrating it with genomic datasets.
If you have further questions or require additional images please reach us here.
Media Contact for Akoya:Christine Quern617firstname.lastname@example.org
Sign up to receive our eNewsletter, new product updates, events, and more!